- Home
- ENVB vs QLGN Comparison
ENVB vs QLGN Comparison
Compare ENVB & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- QLGN
- Stock Information
- Founded
- ENVB 1994
- QLGN 1996
- Country
- ENVB United States
- QLGN United States
- Employees
- ENVB N/A
- QLGN N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ENVB Health Care
- QLGN Health Care
- Exchange
- ENVB Nasdaq
- QLGN Nasdaq
- Market Cap
- ENVB 3.1M
- QLGN 2.8M
- IPO Year
- ENVB N/A
- QLGN N/A
- Fundamental
- Price
- ENVB $1.23
- QLGN $3.32
- Analyst Decision
- ENVB Strong Buy
- QLGN
- Analyst Count
- ENVB 1
- QLGN 0
- Target Price
- ENVB $10.00
- QLGN N/A
- AVG Volume (30 Days)
- ENVB 180.1K
- QLGN 10.5K
- Earning Date
- ENVB 08-11-2025
- QLGN 08-13-2025
- Dividend Yield
- ENVB N/A
- QLGN N/A
- EPS Growth
- ENVB N/A
- QLGN N/A
- EPS
- ENVB N/A
- QLGN N/A
- Revenue
- ENVB N/A
- QLGN N/A
- Revenue This Year
- ENVB N/A
- QLGN N/A
- Revenue Next Year
- ENVB N/A
- QLGN N/A
- P/E Ratio
- ENVB N/A
- QLGN N/A
- Revenue Growth
- ENVB N/A
- QLGN N/A
- 52 Week Low
- ENVB $1.01
- QLGN $2.85
- 52 Week High
- ENVB $11.55
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- ENVB 43.28
- QLGN 37.30
- Support Level
- ENVB $1.19
- QLGN $3.37
- Resistance Level
- ENVB $1.32
- QLGN $3.70
- Average True Range (ATR)
- ENVB 0.07
- QLGN 0.23
- MACD
- ENVB 0.01
- QLGN -0.04
- Stochastic Oscillator
- ENVB 29.41
- QLGN 2.86
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.